Ad-hoc | 22 February 2006 07:28

Fresenius Medical Care reports Fourth Quarter and Full Year 2005 Results

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Fresenius Medical Care reports Fourth Quarter and Full Year 2005 Results Fresenius Medical Care AG & Co. KGaA (“the Company”) today announces its results for the fourth quarter and full year of 2005. Net revenue was $6,772 million, up 9% compared to 2004. Adjusted for currency, net revenue rose 8%. Excluding one-time costs of $22 million, operating income (EBIT) increased by 13% to $961 million, resulting in an operating margin of 14.2%. Excluding one-time costs of $17 million, net income increased by 17% to $472 million. For the full year 2005, earnings per ordinary share rose by 13% to $4.68. The weighted average number of shares outstanding during 2005 was approximately 96.8 million. Total revenue for the fourth quarter 2005 compared to the fourth quarter 2004 increased by 8% (10% at constant currency) to $1,772 million. Excluding one-time costs of $14 million, operating income (EBIT) for the fourth quarter 2005 increased by 14% to $258 million. This resulted in an operating margin of 14.6%. Excluding one-time costs of $11 million, net income increased by 18% to $127 million. For the ninth consecutive year, shareholders can expect to receive an increased annual dividend for the fiscal year 2005. At the Annual General Meeting to be held on May 09, 2006, shareholders will be asked to approve a dividend of € 1.23 per ordinary share, an increase of 10% from 2004 and € 1.29 per preference share, an increase of 9% from 2004. For the full year 2006, the Company expects revenue growth at constant currencies of approximately 25% on a pro forma basis, giving effect to the Renal Care Group (RCG) merger as compared to 2005 reported revenues. Pro forma amounts assume consolidation of RCG’s operations into Fresenius Medical Care for the full twelve months of 2006. For the full year 2006, the Company expects to report revenue of more than $8 billion. The Company’s projected net income growth on a pro forma basis for 2006 is expected to be between 10 and 15 percent, based on the $472 million net income excluding one-time costs, achieved in 2005. Guidance provided by the Company does not take into effect any expected one-time items and the change of accounting principle for stock options – SFAS 123(R) in the fiscal year 2006. The Company expects the after tax impact of the one-time items and SFAS 123(R) to be around $50 million. In addition in 2006, the Company expects capital expenditures on a pro forma basis to be approximately $450 million, and approximately $100 million for acquisitions. Fresenius AG (WKN 578560, 578563) holds approximately 37% of Fresenius Medical Care AG & Co. KGaA’s capital. Fresenius Medical Care AG & Co. KGaA, Represented by Fresenius Medical Care Management AG, Board of Management, Bad Homburg v.d.H., February 22, 2006 (c)DGAP 22.02.2006 ————————————————————————— language: English emitter: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Deutschland phone: +49 (0) 6172- 609 2525 fax: +49 (0) 6172- 609 2301 email: ir@fmc-ag.com WWW: www.fmc-ag.de ISIN: DE0005785802, DE0005785836, WKN: 578580, 578583 indexes: DAX stockmarkets: Amtlicher Markt in Frankfurt; Freiverkehr in Berlin-Bremen, Hannover, Stuttgart, München, Hamburg, Düsseldorf; Foreign Exchange(s) NYSE End of News DGAP News-Service —————————————————————————